Lineage Cell Therapeutics (LCTX) Assets Average (2011 - 2026)
Lineage Cell Therapeutics (LCTX) posted quarterly Assets Average of $111.1 million for Q1 2026, down 1.27% year-over-year from $112.5 million in Q1 2025, and up 9.84% quarter-over-quarter from $101.1 million in Q4 2025.
Lineage Cell Therapeutics (LCTX) Assets Average (2011 - 2026) Analysis & Trends
Lineage Cell Therapeutics' Assets Average history runs 16 years deep, the most recent figure standing at $111.1 million for Q1 2026.
- In Q1 2026, Assets Average fell 1.27% year-over-year to $111.1 million; the TTM figure through Mar 2026 stood at $111.1 million (down 1.27% YoY), while the FY2025 annual figure was $112.9 million, up 5.4% from the prior year.
- Assets Average for Q1 2026 stood at $111.1 million, up from $101.1 million in the prior quarter.
- The five-year high for Assets Average was $159.5 million in Q1 2022, with the low at $90.2 million in Q3 2025.
- The 5-year median for Assets Average is $108.9 million (2023), against an average of $113.8 million.
- The sharpest annual moves came in 2022 and 2023: Assets Average surged 35.27% in 2022, then declined 25.76% in 2023.
- Lineage Cell Therapeutics' Assets Average stood at $127.4 million in 2022, then fell by 18.7% to $103.6 million in 2023, then advanced by 1.27% to $104.9 million in 2024, then declined by 3.62% to $101.1 million in 2025, then climbed by 9.84% to $111.1 million in 2026.
- Business Quant data shows LCTX's Assets Average at $111.1 million in Q1 2026, $101.1 million in Q4 2025, and $90.2 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 26.95 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 41.30 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 3.29 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 8.86 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 16.08 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 19.82 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 5.34 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 2.09 Bn |
| 10 | Lineage Cell Therapeutics | 270.61 Mn | 212.77 Mn | 1.07 Mn | 107.88 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 107.88 Mn |
| Mar 31, 2026 | 111.06 Mn |
| Dec 31, 2025 | 101.11 Mn |
| Sep 30, 2025 | 90.22 Mn |
| Jun 30, 2025 | 101.28 Mn |
| Mar 31, 2025 | 112.49 Mn |
| Dec 31, 2024 | 104.91 Mn |
| Sep 30, 2024 | 99.70 Mn |
| Jun 30, 2024 | 105.64 Mn |
| Mar 31, 2024 | 104.75 Mn |
| Dec 31, 2023 | 103.59 Mn |
| Sep 30, 2023 | 108.92 Mn |
| Jun 30, 2023 | 112.45 Mn |
| Mar 31, 2023 | 118.43 Mn |
| Dec 31, 2022 | 127.41 Mn |
| Sep 30, 2022 | 133.54 Mn |
| Jun 30, 2022 | 140.22 Mn |
| Mar 31, 2022 | 159.53 Mn |
| Dec 31, 2021 | 152.88 Mn |
| Sep 30, 2021 | 132.98 Mn |